var data={"title":"Varicella-zoster immune globulin (human): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Varicella-zoster immune globulin (human): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/325021?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=varicella-zoster-immune-globulin-human-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Varicella-zoster immune globulin (human): Pediatric drug information&quot;</a> and <a href=\"topic.htm?path=varicella-zoster-immune-globulin-human-patient-drug-information\" class=\"drug drug_patient\">see &quot;Varicella-zoster immune globulin (human): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16317530\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>VariZIG</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5088784\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>VariZIG</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5088788\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Blood Product Derivative;</li>\n      <li>\n        Immune Globulin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5091379\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Varicella prophylaxis: </b>IM: &ge;40.1 kg: 625 units. Administer a single dose based on body weight. Dose may be repeated for high-risk patients with additional exposure &gt;3 weeks after initial administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Administration should begin as soon as possible (ideally within 96 hours) and within 10 days after exposure (CDC 2013). Administration should begin within 96 hours (ideally 48 hours) in hematopoietic cell transplant (HCT) recipients who are exposed to varicella or zoster or a varicella zoster vaccine who develops a varicella-like rash (Tomblyn 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5091378\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=varicella-zoster-immune-globulin-human-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Varicella-zoster immune globulin (human): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postexposure prophylaxis:</b> Infants, Children, and Adolescents: IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&le;2 kg: 62.5 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">2.1 to 10 kg: 125 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">10.1 to 20 kg: 250 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">20.1 to 30 kg: 375 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">30.1 to 40 kg: 500 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;40.1 kg: Refer to adult dosing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Administration should begin as soon as possible (ideally within 96 hours) and within 10 days after exposure (CDC 2013). Administration should begin within 96 hours (ideally 48 hours) in hematopoietic cell transplant (HCT) recipients who are exposed to varicella or zoster or a varicella zoster vaccine who develops a varicella-like rash (Tomblyn 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5091380\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45665623\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45665624\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16317957\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intramuscular [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">VariZIG: 125 units/1.2 mL (1.2 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intramuscular [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">VariZIG: 125 units (1 ea [DSC]) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5088786\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5091381\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IM: For IM administration. Bring to room temperature prior to use. Administer into deltoid muscle or anterolateral aspect of upper thigh in &ge;2 injections depending on patient size. Avoid gluteal region as a routine injection site (due to risk of sciatic nerve injury); only use the upper, outer quadrant if used. Do not use &gt;3 mL per injection site.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5088789\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Varicella prophylaxis: </b>Postexposure prophylaxis of varicella in high-risk individuals. High-risk groups include immunocompromised children and adults, newborns of mothers with varicella shortly before or after delivery, premature infants, neonates and infants &lt;1 year, adults without evidence of immunity, and pregnant women.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends varicella-zoster immune globulin (VZIG) to patients who are at high risk for severe varicella infection and complications; and who were exposed to varicella or herpes zoster; and for whom varicella vaccine is contraindicated. The decision to use VZIG should take into consideration if the patient lacks evidence of immunity; if exposure is likely to result in an infection; and if the patient is at greater risk for varicella complications than the general population. The following are patient groups for whom VZIG is recommended (CDC 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunocompromised patients without evidence of immunity (seronegative), including those with neoplastic disease (eg, leukemia or lymphoma); primary or acquired immunodeficiency; immunosuppressive therapy (including steroid therapy equivalent to prednisone &ge;2 mg/kg or 20 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Newborn of mother who had onset of varicella (chickenpox) within 5 days before delivery or within 48 hours after delivery</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hospitalized premature infants (&ge;28 weeks' gestation) who were exposed during the neonatal period and whose mother has no evidence of immunity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hospitalized premature infants (&lt;28 weeks' gestation or &le;1,000 g) regardless of maternal history and who were exposed during the neonatal period</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnant women without evidence of immunity who have been exposed</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25497698\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>VZV postexposure prophylaxis in hematopoietic cell transplant (HCT) recipients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5088782\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Varicella virus vaccine has been given in error (instead of the indicated varicella immune globulin) to pregnant women exposed to varicella.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5090640\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (2% to 4%), chills (&le;2%), fatigue (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (2% to 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Deep vein thrombosis, hypersensitivity reaction, serum sickness, thrombosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5090534\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> History of anaphylaxis or severe systemic (hypersensitivity) reactions to human immune globulins; IgA deficiency with antibodies against IgA and a history of hypersensitivity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to any component of the formulation; patients with evidence of immunity to varicella zoster virus (ie, with previous varicella infection or vaccination)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5090535\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Severe hypersensitivity reactions may occur; discontinue immediately and provide appropriate treatment. Patients with known antibodies to IgA have a greater risk of severe hypersensitivity and anaphylactic reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic events: Thrombotic events have been reported with use of immune globulin products; use with caution in patients with multiple cardiovascular risk factors, history of atherosclerosis, advanced age, impaired cardiac output, coagulation disorders, prolonged periods of immobilization, and/or known hyperviscosity disorders. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triglycerides, or monoclonal gammopathies.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with severe thrombocytopenia or any coagulation disorder; IM administration may be contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Varicella zoster immune globulin should be administered as soon as possible following exposure (within 96 hours, preferred) to reduce the severity of varicella. There is no evidence which shows therapy will reduce the incidence of chickenpox infection after exposure to varicella zoster virus, or that it will effect established varicella zoster virus infections. According to the US CDC guidelines, healthy and immunocompromised patients (except bone marrow transplant recipients [BMT]) with positive history of varicella infection are considered immune. BMT patients who had varicella infection <i>prior</i> to transplant are <b>not</b> considered immune. BMT patients who develop varicella infection<i> after</i> transplant <b>are</b> considered immune. Patients who are fully vaccinated, but later became immunocompromised should be monitored closely; treatment with VZIG is not indicated, but other therapy may be needed if disease occurs (CDC 2007). The American Society for Blood and Marrow Transplantation (ASBMT) also has guidelines for use of varicella zoster immune globulin in highly immunosuppressed hematopoietic cell transplant (HCT) recipients who are exposed to varicella or zoster or to a varicella zoster vaccinee who has a varicella-like rash. Highly-immunosuppressed patients include those &lt;24 months after HCT or &ge;24 months post HCT and on immune suppressive therapy or have chronic graft-versus-host disease (Tomblyn 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300209\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5091362\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9442&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Consult full interaction monograph for dose interval recommendations.  This interaction does not apply to oral Ty21a typhoid vaccine or others listed as exceptions.<b> Exceptions: </b>Influenza Virus Vaccine (Live/Attenuated); Rotavirus Vaccine; Yellow Fever Vaccine; Zoster Vaccine (Live/Attenuated).<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16317535\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5088791\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Endogenous immune globulins cross the placenta. Clinical use of other immunoglobulins suggest that there are no adverse effects on the fetus. Women who do not have evidence of immunity to varicella may be at increased risk of complications if infected during pregnancy. Varicella infection in the mother can also lead to intrauterine infection in the fetus. VZIG is primarily used to prevent maternal complications, not fetal infection (CDC 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16317538\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if this preparation is excreted into breast milk; endogenous immune globulins can be found in breast milk (Agarwal 2011). The manufacturer recommends that caution be exercised when administering to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5091384\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Baseline assessment of blood viscosity in patients at risk for hyperviscosity; signs and symptoms of varicella infection for 28 days after VZIG administration (CDC 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5091369\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Antibodies obtained from pooled human plasma of individuals with high titers of varicella-zoster provide passive immunity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5091371\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: &ge;6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Metabolized in the reticuloendothelial system</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 100%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IV: 18 to 24 days; IM: 26.2 &plusmn; 4.6 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: IV: &lt;3 hours; IM: 4.5 &plusmn; 2.8 days  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570491\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (VariZIG Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125UNIT/1.2ML (1.2 mL): $1,722.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539992\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>VariQuin (NL);</li>\n      <li>Varitect (AR, AT, CH, CO, CZ, DE, GR, IT, PL, UY);</li>\n      <li>Varitect-CP (IN);</li>\n      <li>Vazigam (ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity.<i> Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varicella-zoster-immune-globulin-human-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Agarwal S, Karmaus W, Davis S, et al, &quot;Immune Markers in Breast Milk and Fetal and Maternal Body Fluids: A Systematic Review of Perinatal Concentrations,&quot; <i>J Hum Lact</i>, 2011, 27(2):171-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varicella-zoster-immune-globulin-human-drug-information/abstract-text/21678611/pubmed\" target=\"_blank\" id=\"21678611\">21678611</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;FDA Approval of an Extended Period for Administering VariZIG for Postexposure Prophylaxis of Varicella,&quot; <i>MMWR Morb Mortal Wkly Rep</i>, 2012, 61:212<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varicella-zoster-immune-globulin-human-drug-information/abstract-text/22456121/pubmed\" target=\"_blank\" id=\"22456121\">22456121</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control, &ldquo;Prevention of Varicella, Recommendations of the Advisory Committee on Immunization Practices (ACIP), &rdquo; <i>MMWR Recomm Rep</i>, 2007, 56(RR4);1-40. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varicella-zoster-immune-globulin-human-drug-information/abstract-text/17585291/pubmed\" target=\"_blank\" id=\"17585291\">17585291</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Updated Recommendations for Use of VariZIG - United States, 2013,&quot; <i>MMWR Morb Mortal Wkly Rep</i>, 2013, 62(28):574-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varicella-zoster-immune-globulin-human-drug-information/abstract-text/23863705/pubmed\" target=\"_blank\" id=\"23863705\">23863705</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varicella-zoster-immune-globulin-human-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen A, Moschopoulos P, Stiehm RE, et al, &quot;Congenital Varicella Syndrome: The Evidence for Secondary Prevention With Varicella-Zoster Immune Globulin,&quot; <i>CMAJ</i>, 2011, 183(2):204-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varicella-zoster-immune-globulin-human-drug-information/abstract-text/21262937/pubmed\" target=\"_blank\" id=\"21262937\">21262937</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varicella-zoster-immune-globulin-human-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lamont RF, Sobel JD, Carrington D, et al, &quot;Varicella-Zoster Virus (Chickenpox) Infection in Pregnancy,&quot; <i>BJOG</i>, 2011, 118(10):1155-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varicella-zoster-immune-globulin-human-drug-information/abstract-text/21585641/pubmed\" target=\"_blank\" id=\"21585641\">21585641</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varicella-zoster-immune-globulin-human-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sendelbach DM and Sanchez PJ, &quot;Varicella, Influenza: Not Necessary to Separate Mother and Infant,&quot; <i>Pediatrics</i>, 2012 , 130(2):e464. 22855925.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varicella-zoster-immune-globulin-human-drug-information/abstract-text/22855925/pubmed\" target=\"_blank\" id=\"22855925\">22855925</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity.<i> Lancet</i>. 1995;345(8960):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varicella-zoster-immune-globulin-human-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomblyn M, Chiller T, Einsele H et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/varicella-zoster-immune-globulin-human-drug-information/abstract-text/19747629/pubmed\" target=\"_blank\" id=\"19747629\">19747629</a>]</span><span class=\"doi\">10.1016/j.bbmt.2009.06.019</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Varizig (varicella zoster immune globulin [human]) lyophilized powder for injection [prescribing information]. Baltimore, MD: Cangene BioPharma Inc; December 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Varizig (varicella zoster immune globulin [human]) solution for injection [prescribing information]. Berwyn, PA: Aptevo BioTherapeutics LLC; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Varizig (varicella zoster immune globulin [human]) solution for injection [product monograph]. Winnipeg, Manitoba, Canada: Emergent BioSolutions Inc; December 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9442 Version 118.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F16317530\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F5088784\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F5088788\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F5091379\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F5091378\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F5091380\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F45665623\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F45665624\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F16317957\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F5088786\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5091381\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F5088789\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25497698\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5088782\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F5090640\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F5090534\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F5090535\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300209\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F5091362\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F16317535\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5088791\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16317538\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5091384\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F5091369\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F5091371\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570491\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539992\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9442|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=varicella-zoster-immune-globulin-human-patient-drug-information\" class=\"drug drug_patient\">Varicella-zoster immune globulin (human): Patient drug information</a></li><li><a href=\"topic.htm?path=varicella-zoster-immune-globulin-human-pediatric-drug-information\" class=\"drug drug_pediatric\">Varicella-zoster immune globulin (human): Pediatric drug information</a></li></ul></div></div>","javascript":null}